top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


18/05/2026







Sacituzumab tirumotecan (Sac‑TMT) delivers survival benefit in advanced endometrial cancer, meeting OS and PFS endpoints over chemotherapy (Ref)


The Phase 3 TroFuse-005 study of sacituzumab tirumotecan (Sac‑TMT), a TROP2-directed ADC, met its primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had progressed after platinum chemotherapy and anti‑PD‑1/L1 immunotherapy


Sac‑TMT is the first ADC to show OS and PFS benefit over chemotherapy in this setting, marking a significant advance for endometrial cancer treatment


The trial also met its objective response rate endpoint. Safety was consistent with prior studies, with no new safety signals














FDA grants Priority Review to Bayer’s HYRNUO® (sevabertinib) for first-line treatment of HER2-mutated NSCLC (Ref)


The US FDA has granted Priority Review to Bayer’s supplemental new drug application for HYRNUO® (sevabertinib) as a first-line treatment for HER2-mutated non-small cell lung cancer (NSCLC) in patients with no prior therapy


The first-line submission is supported by preliminary data from Cohort F of the Phase I/II SOHO-01 trial (NCT05099172), which evaluates efficacy and safety in untreated HER2-mutated NSCLC patients




Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page